|Bid||0.8700 x 1800|
|Ask||0.8701 x 1800|
|Day's Range||0.8690 - 0.8760|
|52 Week Range||0.3400 - 0.8800|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||0.22|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech companies are racing to develop vaccines and treatments as the coronavirus outbreak continues to spread. Yahoo Finance’s Anjalee Khemlani joins Dan Roberts, Julia La Roche and NYU Marketing Professor Scott Galloway on YFi PM to discuss the latest developments.
Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial donations made in 2015 and 2016 to an independent charity patient assistance foundation that aided patients living with multiple sclerosis.
Sanofi SA has agreed to pay $11.85 million to resolve U.S. allegations that it used a charity that helps cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use a high-priced multiple sclerosis drug. The deal, announced by the U.S. Justice Department on Friday, was the latest to result from an industry-wide probe of drugmakers' financial support of patient assistance charities that has resulted in more than $865 million in settlements. The government said Sanofi provided payments to one such charity, The Assistance Fund, not with a charitable purpose in mind but instead to use it as a means to cover the co-pay obligations of Medicare patients using the MS drug Lemtrada.
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
Sanofi (SNY) plans to combine its API commercial activities with six of its European API production sites and spin-off the same into an independent European API company.
Sanofi plans to create a standalone company dedicated to making active pharmaceutical ingredients (API), components that are biologically active in a drug, and will decide whether to list it on Euronext Paris by 2022. The French drugmaker on Monday said it would create the business on the back of the combination of its API commercial and development activities with six of its European API production sites in Italy, Germany, Britain, France and Hungary. Europe's pharmaceutical sector is highly dependent on raw materials and active ingredients from Asia, buying products from companies mostly based in China and India.
The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly. Large national regulators, including the U.S. Food and Drug Administration and United Kingdom's National Institute for Health and Care Excellence (NICE), are considering increasing the use of data gathered outside of clinical trials on the effectiveness of treatments, often referred to as real-world data. The FDA is running a pilot project using Aetion's database of insurance claims to replicate clinical trial results, as part of a requirement to comply with healthcare legislation called the 21st Century Cures Act.
The drugmaker plans to float a 70 per cent stake in the new standalone company on the Paris stock exchange, creating what it called a “new industry champion” that would help Europe ensure adequate supply of pharmaceutical ingredients and prevent drug shortages.
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Sanofi will work with a division of the U.S. Health and Human Services Department, with plans to revive work on an advanced prevaccine drug that more than a decade ago it started to develop to combat SARS.
Sanofi said on Tuesday it was working with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health Department to develop a vaccine against the new coronavirus from China. The French drugmaker said it intended to further investigate an advanced pre-clinical vaccine candidate previously developed against the SARS virus in the early 2000s, which it believes could protect against the latest coronavirus. Johnson & Johnson said last week it was collaborating with BARDA to speed up development of a coronavirus vaccine.
Sanofi (NASDAQ: SNY; EURONEXT: SAN) Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company's long-standing partnership with BARDA.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Regeneron profit was better than expected for the fourth quarter. Sales also beat. But shares dipped Friday. The company said it will provide 2020 guidance by the end of the first quarter.
French drugmaker Sanofi will announce a new coronavirus initiative within the next two weeks, its chief executive said on Thursday, adding that it wants to present something concrete and not add to "fantasies". "We have seen a flurry of activities from other companies," CEO Paul Hudson told a news conference after Sanofi published 2019 results on Thursday. Hudson declined to give further details.
French drugmaker Sanofi on Thursday forecast further profit growth for 2020 even as it drops some research in areas such as diabetes in a shake-up to narrow its focus on blockbuster treatments including eczema medicine Dupixent. Sanofi, long viewed as a laggard in the pharmaceutical sector, has changed its chief executive, its chief financial officer and head of research over the past two years and is hoping to shine again thanks to the pipeline shake-up and cost cuts. EPS growth reached 6.8% in 2019 as net income rose 7% to 7.5 billion euros ($8.25 billion).